Topics

Clinical Trials About "Alkermes Announces Data From ALKS 4230 Clinical Development" RSS

10:20 EST 6th December 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Alkermes Announces Data From ALKS 4230 Clinical Development" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Alkermes Announces Data From ALKS 4230 Clinical Development" on BioPortfolio

We have published hundreds of Alkermes Announces Data From ALKS 4230 Clinical Development news stories on BioPortfolio along with dozens of Alkermes Announces Data From ALKS 4230 Clinical Development Clinical Trials and PubMed Articles about Alkermes Announces Data From ALKS 4230 Clinical Development for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alkermes Announces Data From ALKS 4230 Clinical Development Companies in our database. You can also find out about relevant Alkermes Announces Data From ALKS 4230 Clinical Development Drugs and Medications on this site too.

Showing "Alkermes Announces Data From ALKS 4230 Clinical Development" Clinical Trials 1–25 of 26,000+

Extremely Relevant

A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors

To better understand the safety and tolerability of ALKS 4230 in humans


A Study of ALKS 4230 With Pembrolizumab in Head and Neck Cancer

The primary objective of this study is to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who have previously received anti-PD-(L)1 therapy but who have not achieved a CR.

A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)

This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.


Relevant

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.

A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers

This study will evaluate the impact of CYP3A4 induction on the single-dose pharmacokinetics of ALKS 5461.

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study

This study will evaluate the efficacy and safety of ALKS 5461.

A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users

This study will evaluate the abuse potential of ALKS 5461.

A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.

A Water Consumption Study of ALKS 5461 in Healthy Volunteers

This study will evaluate the impact of water consumption on the pharmacokinetics of ALKS 5461.

A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

This study will evaluate the efficacy of ALKS 5461 when administered daily for 4 weeks to adults with Major Depressive Disorder (MDD) and inadequate response to antidepressant therapy.

A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation

The purpose of this study is to assess the safety and tolerability of RDC-1036 (ALKS 37) in adults with opioid-induced constipation following repeat dose administration

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 3831 in subjects with schizophrenia.

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) (the EVOLVE-1 Study)

This study will evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

The primary objective of this study is to evaluate the long term safety and tolerability of ALKS 3831 in subjects with schizophrenia.

A Pilot Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder

The purpose of this study is to evaluate the safety and efficacy of daily doses of RDC-0313 (ALKS 33) compared with placebo in adults with binge eating disorder.

A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

This study will assess the long-term safety and tolerability of ALKS 5461 as an adjunctive treatment for refractory MDD.

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

This study will assess the gastrointestinal (GI) tolerability of ALKS 8700 in adult subjects with RRMS

Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function

This study will evaluate the effect of various degrees of renal function on the pharmacokinetics and safety of ALKS 5461.

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

This study will evaluate the effect of ALKS 3831 compared to olanzapine on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness

A Phase 1 Safety Study in Adults With Schizophrenia

This study will determine the safety, tolerability, and pharmacokinetics (PK) of olanzapine and samidorphan in adults with schizophrenia following 14 consecutive days of oral administration of ALKS 3831.

A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

This study will evaluate the efficacy of ALKS 3831 in adult subjects with acute exacerbation of schizophrenia.

An Insulin Sensitivity Study in Healthy Subjects

This study will characterize insulin sensitivity in response to treatment with ALKS 3831, olanzapine, and placebo.

Clinical Investigation Plan for the AVOPT Data Collection Clinical Study

The purpose of this study is to collect clinical data for the development and evaluation of a new device feature for automatic AV-delay (AVD) optimization.

Collecting Orthopedic Safety and Performance Data Using Surgeons Clinical Outcomes Registry (SCOR)

The Surgeons Clinical Outcomes Registry (SCOR) is a global registry designed to collect safety and performance data on commercially available Wright Medical products. Registry data may be used for publications, education and marketing materials, post-market surveillance, future regulatory submissions, research and development for product design, software improvements, and development of artificial intelligence learning and tools.


More From BioPortfolio on "Alkermes Announces Data From ALKS 4230 Clinical Development"

Quick Search